Antiplatelet drugs overview

Sarah Younis Latif; Mustafa Mohammed Issa; Tabark Najah Hassan; Murtadha Haider Ali

doi:10.30574/gscbps.2020.10.1.0003

Authors

Sarah Younis Latif College of Pharmacy, Al-Nahrain University, Iraq.
Mustafa Mohammed Issa College of Pharmacy, Al-Nahrain University, Iraq.
Tabark Najah Hassan College of Pharmacy, Al-Nahrain University, Iraq.
Murtadha Haider Ali College of Pharmacy, Al-Nahrain University, Iraq.

DOI:

https://doi.org/10.30574/gscbps.2020.10.1.0003

Keywords:

Aspirin, Thienopyridines, Coronary heart disease

Abstract

Platelets are essential factor in the pathophysiology of atherothrombosis, abnormal platelet function guiding to many cardiovascular complications such as myocardial infarction and ischemic stroke. There are numerous antiplatelet drugs approved for use in the clinical management and several under examination. Antiplatelet drugs with the high potency are mostly associated with the intensifying incidence of bleeding. Aspirin and clopidogrel (alone or dual) are the mostly used drugs with the best favorable risk-benefit profiles of drugs available. While cangrelor and ticagrelor may produce further benefits but need more studies .Other drugs such as prasugrel, dipyridamole and cilostazol are not widely used.

Metrics

Metrics Loading ...

References

Bhatt DL. (2009). Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. American journal of cardiology, 103, 11A–9A.

Kaushansky K. (2009).Determinants of platelet number and regulation of thrombopoiesis. Hematology- American Society of Hematology Education Program, (1), 147 - 152.

Davì G and Patrono C. (2007). Platelet activation and atherothrombosis. New England Journal of Medicine, 357(24), 2482 - 2494.

Di Minno MND, Guida A, Camera M, Colli S , Di Minno G, and Tremoli E. (2011).Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention. Annals of Medicine, 43, 531–544.

Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, et al . (2001).Activated platelets mediate infl ammatory signaling by regulated interleukin 1-beta synthesis.Journal of Cell Biology, 154(3), 485 - 490.

Rada FH. (2018). Oxidative stress and some inflammatory biomarkers in patients with coronary heart disease. European journal of pharmaceutical and medical research, 5(1), 9 -12.

Patrono C, Baigent C, Hirsh J and Roth G. (2008). Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest,133, 199S–233S

Cox D, Maree AO, Dooley M, Conroy R, Byrne MF and Fitzgerald DJ. (2006). Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke, 37(8), 2153 - 2158.

Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al . (1985). Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation, 72(6), 1177 - 1184.

Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, et al. (2002). Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. New England Journal of Medicine, 346, 2033–8.

US Food and Drug Administration. (2010). Information for Healthcare Professionals: Concomitant Use of Ibuprofen and Aspirin. Rockville, MD: FDA Medwatch.

Cattaneo M. (2007). Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. Journal of Thrombosis and Haemostasis, 5, 230–7.

DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. (2007). The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes, 56, 3014–9.

Savi P and Herbert JM. (2005).Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Seminars in Thrombosis and Hemostasis, 31(2), 174 - 183.

Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, et al. (1998). Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation, 98, 2126 – 32.

CAPRIE Steering Committee. (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329–39.

Rada FH. (2016). Clopidogrel and liver injury in diabetic patients. European journal of pharmaceutical and medical research, 3(6), 168-170.

Hasan NA, Al Baghdadi MH and Rada FH. (2014). Assessment of adverse effect of atorvastatin with platelet P2Y12-ADP receptor antagonist on platelets aggregation and renal function in coronary heart disease treated patients. International journal of research in pharmacy and chemistry, 4(2), 274-282.

Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS II, Brandt JT, et al. (2007). Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clinical Pharmacology and Therapeutics, 81, 735–41.

Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, et al. (2005).Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation, 111, 2560–4.

Shuldiner AR,O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Journal of the American Medical Association, 302, 849–57.

Cuisset T , Frere C , Quilici J , Morange PE, Nait-Saidi L ,Carvajal J, et al .(2006). Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting .Journal of American College of Cardiology , 48 (7),1339 - 1345 .

Serebruany VL, Malinin AI, Ferguson JJ, Vahabi J, Atar D and Hennekens CH. (2008). Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundamental and Clinical Pharmacology, 22, 315–21.

Rada FH, Hasan NA and Al Baghdadi MH. (2015). Hepatotoxicity of Combined Therapy of Atorvastatin with Platelet P2Y12-ADP Receptor Antagonist in Coronary Heart Disease Treated Patients. The Iraqi Postgraduate Medical Journal, 14(1), 108 -113.

Rada FH. (2019).Peroxisome Proliferator- Activated Receptors Family Overview. European Journal of Pharmaceutical and Medical Research, 6(1), 167-170.

Siller-Matula JM, Lang I, Christ G and Bernd Jilma B. (2008).Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. Journal of the American College of, 52, 1557-1563.

Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ and Becker R. (2010).Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Journal of American College of Cardiology, 56 (12), 919 - 933.

Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, et al. (2006). Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metabolism and Disposition, 34, 600–7.

Braun OO, Johnell M, Varenhorst C, James S, Brandt JT, Jakubowski JA, et al.(2008). Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.Thrombosis and Haemostasis, 100, 626–33.

Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE and Kurihara A. (2007). The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metabolism and Dispositions, 35 (7), 1096-8.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357, 2001–15.

Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, et al. (2008).Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Journal of Clinical Pharmacology, 48, 475–84.

Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, et al. (2008).Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. Journal of American College of Cardiology, 52, 1968–77.

Storey RF, Wilcox RG and Heptinstall S. (2002). Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets, 13, 407–13.

Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, et al. (2009). Platelet inhibition with cangrelor in patients undergoing PCI.New England Journal of Medicine, 361, 2318–29.

Fugate SE and Cudd LA. (2006).Cangrelor for treatment of coronary thrombosis. Annals of Pharmacotherapy, 40, 925–30.

Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G,et al. (2009). Intravenous platelet blockade with cangrelor during PCI. New England Journal of Medicine, 361, 2330 – 41.

Steinhubl SR, OH JJ, Oestreich JH, Ferraris S, Charnigo R and Akers WS. (2008).Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thrombosis Research, 121, 527–34.

Rada FH. (2018).Antiplatelet Adequacy of Cytopentyl Triazolopyrimidine versus Clopidogrel in Patients with Coronary Heart Disease. Asian Journal of Pharmaceutical and Clinical Research, 11(12), 536 -539.

Teng R and Butler K. (2010). Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P 2Y(12) receptor antagonist,in healthy subjects. European Journal of Clinical Pharmacology, 66, 487–96.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 361, 1045–57.

Bhatt DL. (2007).Intensifying platelet inhibition-navigating between Scylla and Charybdis. New England Journal of Medicine, 357, 2078 – 81.

Born G and Patrono C. (2006). Antiplatelet drugs. British Journal of Pharmacology, 147 (1) , S241 - S251 .

Müller TH, Su CA, Weisenberger H, Brickl R, Nehmiz G and Eisert WG. (1990). Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. British Journal of Clinical Pharmacology, 30(2), 179 - 186.

Weinberger J. (2005).Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Drugs, 65, 461–71.

Serebruany VL, Malinin AI, Eisert RM and Sane DC. (2004). Risk of bleeding complications with antiplatelet agents: metaanalysis of 338,191 patients enrolled in 50 randomized controlled trials. American Journal of Hematology, 75, 40–7.

Thompson PD, Zimet R, Forbes WP and Zhang P. (2002). Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. American Journal of Cardiology, 90 (12), 1314 - 5.

Biondi-Zoccai GG ,Lotrionte M , Anselmino M , Moretti C, Agostoni P, Testa L,et al.(2008). Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. American Heart Journal, 155 (6), 1081 - 8.

Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, et al.(2008). A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.European Heart Journal, 29, 2202 – 11.

Hiratsuka M, Hinai Y, Sasaki T, Konno Y, Imagawa K, Ishikawa M, et al. (2007).Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metabolism and Disposition, 35, 1730–2.

Gamssari F, Mahmood H, Ho JS, Villareal RP, Liu B, Rasekh A, et al.(2002). Rapid ventricular tachycardias associated with cilostazol use. Texas Heart Institute Journal, 29, 140–2.

Suri A, Forbes WP, Bramer SL. (1999). Effects of CYP3A inhibition on the metabolism of cilostazol. Clinical Pharmacokinetics, 37, 61–8.

Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, et al.(1996). Randomized,double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.Journal of American College of Cardiology,27 (3), 536 - 542 .

Sharma HL and Sharma KK. (2007). Principles of pharmacology. 1st ed. Hyderabad: Paras medical publishers; Drugs affecting coagulation, fibrinolysis and platelet functions, 639, 703,704.

Tcheng JE, Kereiakes DJ , Lincoff AM , George BS, Kleiman N, Sane DC, et al .(2001). Abciximab readministration: results of the ReoPro Readministration Registry. Circulation, 104 (8), 870 - 875.

Gross PL and Weitz JI. (2009).New antithrombotic drugs. Clinical Pharmacology and Therapeutics, 86, 139-46.